Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-09

Clinical Trial Update: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of once-weekly semaglutide added to metformin versus once-daily sitagliptin added to metformin in adults with type 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sitagliptin (sitagliptin)
  • metformin (metformin)
  • semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2020-04-09